Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis

Arthritis and Rheumatism

Volumn 42, Issue 6, 1999, Pages 1246-1254

  Hochberg, Marc C ^a,e   Ross, Philip D ^b   Black, Dennis ^c   Cummings, Steven R ^c   Genant, Harry K ^e   Nevitt, Michael C ^c   Barrett Connor, Elizabeth ^d   Musliner, Thomas ^b   Thompson, Desmond ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK MANAGEMENT; SPINE RADIOGRAPHY; VERTEBRA FRACTURE;

NON-PROGRAMMATIC;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; FEMALE; FEMUR NECK; FRACTURES, SPONTANEOUS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES;

EID: 0033039349     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U     Document Type: Article

References (31)

1. Ross PD, Davis JW, Epstein R, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence. Ann Intern Med 1991;114:919-23.
2. Seeley D, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR, for the Study of Osteoporotic Fractures Research Group. Which fractures are associated with low appendicular bone mass in elderly women. Ann Intern Med 1991;115:837-42.
3. Nevitt MC, Johnell O, Black DM, Ensrud K, Genant HK, Cummings SR. Bone mineral density predicts fractures in very elderly women. Osteoporos Int 1994;4:325-31.
4. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
5. Sklarin PM, Cummings SR, Nevitt MC, Ensrud K, Stone KT, Black DM, for the Study of Osteoporotic Fractures Research Group. Bone loss is an independent predictor of hip fracture in elderly women with low bone mass [abstract]. 10th International Congress of Endocrinology; 1996 June 12-15; San Francisco.
6. Black DM, Cummings SR, Karpf DB, Cauley J, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
7. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al, for the FIT Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-82.
8. Cummings SR, Black DM, Vogt TM, for the FIT Research Group. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drags [abstract]. J Bone Miner Res 1996;11:S102.
9. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR, for the Fracture Intervention Trial Research Group. Design of the Fracture Intervention Trial. Osteoporos Int 1993;3 Suppl 3:S29-39.
10. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-8.
11. Liberman U, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
12. Cummings SR, Block G, McHenry K, Baron RB. Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol 1987;126:796-802.
13. Cummings SR, Mellon LJ III, Felsenberg D, Allander E, Black D, Cooper C, et al. National Osteoporosis Foundation Working Group on Vertebral Fractures report: assessing vertebral fractures. J Bone Miner Res 1995;10:518-23.
14. Genant HK, Jergas M, van Kuijk C, editors. Vertebral fracture in osteoporosis. San Francisco: Radiology Research and Educational Foundation; 1995.
15. Huang C, Ross PD, Fujiwara S, Davis JW, Epstein RS, Kodama K, et al. Determinants of vertebral fracture prevalence among native Japanese women and women of Japanese descent living in Hawaii. Bone 1996;18:437-42.
16. Lunt M, Felsenberg D, Reeve J, Benevolenskaya L, Cannata J, Dequeker J, et al. Bone density variation and its effect on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS study. J Bone Miner Res 1997;12:1883-94.
17. Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 1996; 19:9-12.
18. Garnero P, Hausherr E, Chapuy M-C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11:1531-8.
19. Ross PD, Wasnich RD, Knowlton WK. Skeletal alkaline phosphatase (Tandem®-R Ostase®) measurements predict vertebral fractures: a prospective study [abstract]. J Bone Miner Res 1997;12 Suppl:S150.
20. Van Daele PLA, Seibel MJ, Burger H, De Laet CEDH, van Leeuwen JPTM, Hofman A, et al. Evidence for uncoupling of bone formation and bone resorption in women with hip fractures: a prospective study [abstract]. Osteoporos Int 1996;6 Suppl 1:S199.
21. Szulc P, Chapuy M-C, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 1996;18:487-8.
22. Parfitt AM. Bone age, mineral density, and fatigue damage. Calcif Tissue Int 1993;53 Suppl:S82-6.
23. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80.
24. Heaney RP, Yates AJ, Santora AC. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 1997;12:1143-51.
25. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431-8.
26. Bauer DC, Black DM, Ott SM, Santora A, Thompson D, Ennis M, et al, for the Fracture Intervention Trial Research Group. Biochemical markers predict spine but not hip BMD response to alendronate: the Fracture Intervention Trial [abstract]. J Bone Miner Res 1997;12 Suppl 1:S150.
27. Ott SM, Bauer DC, Santora A, Thompson DE. Ability of bone biochemical markers to predict 4-year changes in bone density in postmenopausal women [abstract]. Bone 1998;23 Suppl 5:S159.
28. Rodan G. Bone mass homeostasis and bisphosphonate action. Bone 1997;20:1-4.
29. Dempster DW. Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis. J Bone Miner Res 1997;12:1152-4.
30. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 1998;21:373-7.
31. Dawson-Hughes B, Dallal GE. Effect of radiographic abnormalities on rate of bone loss from the spine. Calcif Tissue Int 1990;46:280-1.